The Globe and Mail

Bristol-Myers Squibb’s Luspatercept Study: A Potential Game-Changer for Myelodysplastic Syndrome

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: Bristol-Myers Squibb is ...
Business Wire

Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases ...
Targeted Oncology

Real-world Outcomes with Luspatercept

A recent study highlights the effectiveness of Luspatercept in first-line treatment, showing significant patient benefits and ...
The American Journal of Managed Care

COMMANDS: Luspatercept Boosts Population With Lower-Risk Myelodysplastic Syndromes Who Are Freed From Blood Transfusions

The study's lead author said patients would experience improved quality of life due to fewer transfusions and fewer trips to the clinic to receive treatment. More patients at risk of anemia from lower ...
Healio

Luspatercept ‘a paradigm shift’ in transfusion-dependent myelodysplastic syndrome

Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...
The American Journal of Managed Care

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Luspatercept shows higher efficacy than ESAs in increasing hemoglobin levels and sustaining improvement in LR-MDS patients. Patients treated with luspatercept achieve faster and more sustained red ...
Healio

VIDEO: COMMANDS study shows luspatercept as option for low-risk myelodysplastic syndrome

Please provide your email address to receive an email when new articles are posted on . In this video, Eunice Wang, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk ...
News Medical

Treatment with luspatercept improves red blood cell counts in patients with myelodysplastic syndromes

Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no ...
Monthly Prescribing Reference

Outcomes in Nontransfusion-Dependent β-Thalassemia With Luspatercept or Placebo

Credit: Shutterstock. Researchers sought to determine whether luspatercept would improve outcomes in patients with nontransfusion-dependent β-thalassemia. The following article features coverage from ...
The Globe and Mail

Bristol-Myers Squibb’s Luspatercept Study: A Potential Game-Changer for Anemia Treatment

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: Bristol-Myers Squibb is ...